{"title":"ASCO21 -肾癌患者的关键更新","authors":"Neil J. Shah","doi":"10.52733/kcj19n2-s1-a14","DOIUrl":null,"url":null,"abstract":"Over the last decade, novel immunotherapies and targeted therapies have revolutionized the kidney cancer treatment landscape. ASCO Annual Meeting, 2021, was yet another success against this battle, and in this commentary, we will focus on a few critical abstracts presented at the meeting pertinent to kidney cancer.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASCO21 – Key Updates for Kidney Cancer Patients\",\"authors\":\"Neil J. Shah\",\"doi\":\"10.52733/kcj19n2-s1-a14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Over the last decade, novel immunotherapies and targeted therapies have revolutionized the kidney cancer treatment landscape. ASCO Annual Meeting, 2021, was yet another success against this battle, and in this commentary, we will focus on a few critical abstracts presented at the meeting pertinent to kidney cancer.\",\"PeriodicalId\":74040,\"journal\":{\"name\":\"Kidney cancer journal : official journal of the Kidney Cancer Association\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney cancer journal : official journal of the Kidney Cancer Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52733/kcj19n2-s1-a14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney cancer journal : official journal of the Kidney Cancer Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52733/kcj19n2-s1-a14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Over the last decade, novel immunotherapies and targeted therapies have revolutionized the kidney cancer treatment landscape. ASCO Annual Meeting, 2021, was yet another success against this battle, and in this commentary, we will focus on a few critical abstracts presented at the meeting pertinent to kidney cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
